Daniel Saks
Chief Executive Officer
The MedTech industry continues to drive healthcare innovation forward. The global MedTech market was valued at approximately $739.6 billion in 2023. These 12 companies represent the forefront of healthcare innovation. For these rapidly scaling organizations, efficient go-to-market strategies are critical—especially when navigating complex hospital procurement cycles and multi-stakeholder decision-making processes. AI-powered platforms like Landbase's VibeGTM interface enable MedTech companies to identify and qualify high-value prospects in seconds using natural-language targeting, accelerating market penetration in this competitive landscape.
Olympus specializes in diagnostic, therapeutic, and minimally invasive medical procedures with a comprehensive portfolio including endoscopes, laparoscopes, video imaging systems, surgical energy devices, and integrated system solutions. These technologies are used in gastrointestinal, pulmonary, and urological procedures across 100+ countries.
Olympus holds a dominant position in the endoscopy market, providing essential tools for early disease detection and minimally invasive treatment. Their innovation in imaging technology sets industry standards for diagnostic precision and patient outcomes.
Valuation: $14.6 B | Founded: 1919
Boston Scientific develops, manufactures, and markets medical devices globally with focus on interventional procedures in radiology, cardiology, electrophysiology, endoscopy, neuromodulation, and urology. The company pioneered pulsed field ablation (PFA) systems for atrial fibrillation treatment.
Boston Scientific is a major force in interventional medicine, advancing catheter-based treatments that reduce surgical trauma and recovery times. Their portfolio spans multiple high-value therapeutic areas, making them essential to modern cardiovascular and peripheral vascular care.
Valuation: $143.6 B | Founded: 1979
Recent Funding: €1.5 billion (2025)
Intuitive Surgical develops advanced robotic systems for minimally invasive surgery, pioneering the surgical robotics field with its da Vinci surgical system platform. The platform has been used in over 10 million procedures worldwide.
Intuitive Surgical revolutionized surgery by making minimally invasive procedures accessible across multiple specialties. Their robotic platforms enable surgeons to perform complex operations with enhanced precision, reduced patient trauma, and faster recovery times.
Valuation: $592.96 | Founded: 1995
Recent Funding: No recent major private-equity funding disclosed
Abbott is a global healthcare company with a diverse MedTech portfolio including diabetes care (FreeStyle Libre continuous glucose monitoring), neuromodulation devices, cardiovascular diagnostic and treatment technologies, and AI-powered imaging solutions. The company serves millions of patients across multiple therapeutic areas.
Abbott's broad portfolio addresses critical healthcare needs from diabetes management to structural heart disease. Their FreeStyle Libre system has transformed diabetes care globally, while their cardiovascular innovations advance minimally invasive treatment options.
Valuation: $223B | Founded: 1888
Recent Funding: No recent private-equity funding disclosed
Stryker operates across Orthopedics, Medical & Surgical (MedSurg), and Neurotechnology & Spine divisions, offering implants, surgical equipment, AI-driven robotic systems like Mako SmartRobotics™ for knee and hip replacement, and patient care solutions. The company serves hospitals and healthcare facilities worldwide.
Stryker's robotic orthopedic platforms have set new standards for precision in joint replacement surgery. Their comprehensive portfolio across orthopedics, surgical technologies, and neurotechnology makes them indispensable to modern surgical departments.
Valuation: $140.8 B | Founded: 1941
Recent Funding: No recent major private-equity funding disclosed
Tempus leverages AI and data capabilities to transform clinical care and research, utilizing real-time healthcare data to personalize care across oncology, neuropsychiatry, cardiology, infectious disease, and radiology through its Tempus Operating System. The company has built the world's largest library of clinical and molecular data (50+ petabytes).
Tempus is transforming precision medicine by making vast amounts of clinical and molecular data actionable for physicians. Their AI-driven platform enables personalized treatment decisions across multiple disease areas, accelerating the shift toward data-driven healthcare.
Valuation: $1.05B | Founded: 2015
Recent Funding: $411 million IPO (June 2024)
Blackrock Neurotech develops neurotechnology including brain-computer interfaces (BCIs) that help patients with paralysis and neurological disorders regain tactile function, movement of limbs and prosthetics, and ability to control digital devices using thoughts. The company has over 20 years of human BCI experience with a proven track record since 2004.
Blackrock Neurotech is at the forefront of brain-computer interface technology, pioneering solutions that restore function to individuals with severe paralysis. Their extensive clinical experience positions them as leaders in translating neurotechnology from research to clinical application.
Valuation: $350 million | Founded: 2008
Recent Funding: $200 million (April 2024)
Oura develops and markets smart rings that track comprehensive health metrics including sleep, activity, readiness, and physiological signals, combining medical-grade monitoring with consumer-friendly design. The company is developing clinical applications including FDA-clearance pathways for remote patient monitoring.
Oura has created and dominates the smart ring category, bringing continuous health monitoring to a wearable form factor. Their expansion into clinical applications bridges consumer wellness and medical-grade diagnostics, potentially transforming remote patient monitoring.
Valuation: $5.2B | Founded: 2013
Recent Funding: $200 million Series D (2024)
Kestra Medical develops the Assure system, a modern wearable cardioverter defibrillator (WCD) designed to provide autonomous detection and defibrillation for ventricular arrhythmias. The system features specific design considerations for female cardiac patients, addressing a significant gap in women's cardiac health technology.
Kestra Medical is addressing critical gaps in cardiac care for women, who have historically been underserved by one-size-fits-all medical devices. Their gender-specific approach to wearable defibrillators represents an important shift toward personalized cardiac protection.
Valuation: $1.3 billion | Founded: 2014
Recent Funding: $196 million (July 2024)
Caresyntax is a vendor-neutral precision surgery platform developer that transforms surgery with scalable, end-to-end software and AI platform designed to enhance surgical precision, patient safety, and hospital operational efficiency. The platform provides real-time clinical decision support throughout the patient journey.
Caresyntax's vendor-neutral platform addresses a critical need in surgical data integration, enabling hospitals to leverage AI insights regardless of their existing equipment. Their approach to surgical data standardization has the potential to transform operating room efficiency and patient outcomes.
Valuation: $ 500 million | Founded: 2013
Recent Funding: $180 million Series C (August 2024)
Imperative Care is a commercial-stage medical technology company developing connected innovations for vascular diseases including stroke and pulmonary embolism. The company operates through four entities: Imperative Care Stroke, Vascular, Kandu Health, and Telos Health, covering the full stroke care continuum.
Imperative Care's comprehensive platform addresses stroke care beyond the acute intervention phase, integrating devices with digital recovery tools. This holistic approach to vascular disease management represents an evolution in how medical device companies support patient outcomes.
Valuation: $496M | Founded: 2015
Recent Funding: $150 million Series E (July 2024)
Precision Neuroscience develops AI-powered brain-computer interfaces to help users with severe paralysis operate digital devices like computers and smartphones using their thoughts through an ultra-thin Layer 7 Thin-Film BCI. The system features 1,024 electrodes embedded in flexible film one-fifth the thickness of human hair.
Precision Neuroscience's ultra-thin BCI technology offers a less invasive alternative to traditional brain implants. Their approach could expand the addressable market for brain-computer interfaces by reducing surgical risk and enabling broader clinical adoption.
Valuation: $155 million | Founded: 2021
Recent Funding: $102 million Series C (December 2024)
These 12 fastest-growing MedTech companies face a common challenge:
This is where AI-powered audience discovery becomes essential. Landbase's GTM-2 Omni platform enables MedTech companies to use natural-language prompts like "CFOs at hospital systems with 500+ beds that recently announced new facility construction" to instantly generate AI-qualified prospect lists. The platform's 1,500+ unique signals—including funding rounds, hiring patterns, technology stack changes, and conference attendance—help identify healthcare organizations at peak buying readiness.
For MedTech startups emerging from accelerator programs like MedTech Innovator's 2025 cohort, efficient targeting can mean the difference between rapid market penetration and prolonged sales cycles. By leveraging Landbase Intelligence for growth signals and Trust Scores, these companies can prioritize accounts most likely to convert, while the VibeGTM interface simplifies complex multi-parameter searches into simple conversational queries.
Fastest-growing MedTech companies are defined by either significant year-over-year revenue growth (8%+ for established companies) or major funding rounds ($100M+ for startups) in 2024-2025. Growth must be accompanied by market impact, whether through FDA approvals, hospital adoption, or technological innovation. Companies like Olympus achieved approximately 17.6% revenue growth in fiscal 2023, while startups like Blackrock Neurotech secured $200 million in funding. These metrics reflect both financial momentum and clinical or commercial validation in the marketplace.
AI drives MedTech growth through both product innovation and operational efficiency, transforming how companies develop and commercialize medical technologies. On the product side, companies like Abbott developed AI-powered Ultreon OCT for coronary imaging, while Viz.ai uses deep learning to detect strokes on CT scans, reducing treatment time by 30-40 minutes. Operationally, AI-powered GTM platforms help companies identify high-intent prospects based on 1,500+ signals like funding rounds, hiring patterns, and technology stack changes. This dual application of AI—in products and go-to-market strategies—accelerates both innovation cycles and sales velocity in complex healthcare environments.
MedTech startups typically progress through seed, Series A-C, and growth rounds, with recent funding crucial for navigating lengthy FDA approval processes and clinical trials that can take years. The largest 2024 rounds included $200 million for Blackrock Neurotech, $196 million for Kestra Medical, and $180 million for Caresyntax, demonstrating investor confidence in specific therapeutic areas. This capital funds regulatory compliance, manufacturing scale-up, and commercial team expansion—critical for MedTech companies facing 12-24 month sales cycles. Recent funding also signals market validation, helping companies attract clinical partners and hospital customers who prefer financially stable vendors.
MedTech CEOs combine clinical domain expertise with commercial acumen to navigate regulatory landscapes while scaling operations across multiple markets. Leaders like Intuitive Surgical's Gary Guthart have overseen transformation into global surgical robotics pioneers, while Tempus AI's Eric Lefkofsky built a $1.2B+ revenue precision medicine platform from startup to IPO in under a decade. Successful MedTech CEOs balance scientific innovation with go-to-market execution, often leveraging AI-powered tools to efficiently target complex healthcare buying committees. They must also manage relationships with regulators, clinicians, payers, and investors simultaneously—a unique challenge requiring both technical credibility and strategic vision.
Fast-growing MedTech companies face FDA approval processes, medical device regulations, reimbursement policies, and data security compliance that can take years and millions of dollars to navigate. Beyond FDA clearance, securing Medicare reimbursement (like Viz.ai achieved) is often essential for commercial viability. The regulatory burden requires significant capital investment, making efficient go-to-market strategies critical—MedTech companies can use natural-language targeting to identify healthcare organizations already using similar technologies or preparing for regulatory submissions.
MedTech companies can efficiently identify and qualify new customers using AI-powered audience discovery platforms that analyze 1,500+ unique signals across firmographic, technographic, intent, hiring, and funding data. Instead of manual prospecting, teams can use natural-language prompts like "Hospital systems in California with new cardiology department leadership" to instantly generate AI-qualified lists based on buying signals. Platforms like Landbase enable MedTech companies to export up to 10,000 contacts instantly without requiring a login, accelerating market penetration in complex healthcare sales cycles. This approach is particularly valuable for targeting post-funding rounds, new facility openings, technology upgrades, and leadership changes—all indicators of elevated buying readiness in healthcare organizations.
Tool and strategies modern teams need to help their companies grow.
